One in six cancers worldwide are caused by largely treatable or preventable infections

New estimates suggest that one in six cancers, two million a year globally, are caused by largely treatable or preventable infections.

The Lancet Infectious Diseases review, which looked at incidence rates for 27 cancers in 184 countries, found four main infections are responsible.

These four – human papillomaviruses, Helicobacter pylori and hepatitis B and C viruses – account for 1.9 million cases of cervical, gut and liver cancers.

Most cases are in the developing world.

The team from the International Agency for Research on Cancer in France says more efforts are needed to tackle these avoidable cases and recognize cancer as a communicable disease.

The proportion of cancers related to infection is about three times higher in parts of the developing world, such as East Asia, than in developed countries like the UK – 22.9% versus 7.4%, respectively.

Nearly a third of cases occur in people younger than 50 years.

Among women, cancer of the cervix accounted for about half of the infection-related cancers. In men, more than 80% were liver and gastric cancers.

Dr. Catherine de Martel and Dr. Martyn Plummer, who led the research, said: “Infections with certain viruses, bacteria, and parasites are some of the biggest and preventable causes of cancer worldwide

“Application of existing public-health methods for infection prevention, such as vaccination, safer injection practice, or antimicrobial treatments, could have a substantial effect on the future burden of cancer worldwide.”

Vaccines are available to protect against human papillomavirus (HPV) – which is linked to cancer of the cervix – and hepatitis B virus – an established cause of liver cancer.

And experts know that stomach cancer can be avoided by clearing the bacterial infection H. pylori from the gut using a course of antibiotics.

Commenting on the work, Dr. Goodarz Danaei from Harvard School of Public Medicine in Boston, the US, said: “Since effective and relatively low-cost vaccines for HPV and HBV are available, increasing coverage should be a priority for health systems in high-burden countries.”